Neurocrine Bio. (NBIX) PT Lowered to $96 at BMO Capital
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $157.79 +0.66%
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 2 | Down: 6 | New: 12
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 2 | Down: 6 | New: 12
Join SI Premium – FREE
BMO Capital analyst Evan David Seigerman lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $96.00 (from $140.00) while maintaining a Market Perform rating.
You May Also Be Interested In
- Citi Upgrades Coal India Ltd (COAL:IN) to Buy
- Wedbush Downgrades Tscan Therapeutics Inc (TCRX) to Neutral
- Medtronic, Inc. (MDT) PT Raised to $115 at Mizuho
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
